The Philadelphia Eagles listed three players on their initial injury report ahead of their Week 13 matchup against the Baltimore Ravens. The Ravens listed seven players on their initial injury report. Here's the Eagles-Ravens injury report, with analysis... Wednesday notes : • Smith did not play Week 12, but it didn't matter as Saquon Barkley ran all over the Rams. The Ravens are allowing 277.7 passing yards per game, second-worst in the NFL, so this is a game that the Eagles really need Smith to help exploit a Baltimore defensive weakness. • Slay suffered a concussion Week 12 against the Rams. He was replaced in the lineup by Isaiah Rodgers, who gave up a few completions, but also made one of the plays of the night when he forced a red zone fumble that was recovered by the Eagles. • Ringo did not play at all on defense Week 12 despite some garbage time opportunities late in the game. He likely got hurt earlier in the game. • Not shown above are Saquon Barkley, Mekhi Becton, London Dickerson, Lane Johnson, Cam Jurgens, Jordan Mailata, and Josh Sweat, who were all limited with "rest" days. Other notable players on IR, PUP, suspension, etc. • EDGE Brandon Graham (IR) : Graham tore his left triceps in the Eagles' win over the Rams. Before the season, Graham said that the 2024 season, his 15th in the NFL, would be his last. He played very well, and was arguably the team's best edge defender. If indeed his season is over, Graham will have finished with 20 tackles and 3.5 sacks, with his stats not truly showing his actual impact, as has been the case throughout his career. • S James Bradberry (IR) : The Eagles kept Bradberry on their active roster for no good reason at 53-man cutdowns, and then the next day he suffered a "lower body" injury that was originally supposed to keep him out 6-8 weeks. MORE : NFC Hierarchy/Obituary: Week 13 edition Wednesday notes : • The Ravens held a walkthrough, so this is just an estimation. • Roquan Smith is the Ravens' first-team All-Pro linebacker. On the season he has 110 tackles. He did not play Week 12 against the Chargers, but his projected ability to practice on Wednesday in a step in the direction of being able to play again, I guess? He did not practice at all last week. • Van Noy is in his 12th season. He co-leads the Ravens with 8 sacks. • Kolar has 9 catches for 131 yards and a TD this season. He has a broken arm and is out. He'll likely go on IR later in the week. • Maulet is a journeyman slot corner. Backup. Other notable players on IR, PUP, suspension, etc. • DT Michael Pierce : Rotational DT. 15 tackles, 1 sack this season. He had his 21-day practice window opened on Wednesday. • RS Deonte Harty : Ultra-small (5'6, 170) return specialist. MORE : Eagles film review: Josh Sweat is having a bounce-back season Follow Jimmy & PhillyVoice on Twitter: @JimmyKempski | thePhillyVoice Like us on Facebook: PhillyVoice Sports Add Jimmy's RSS feed to your feed reader
The Central Reserve Police Force's (CRPF) timely intervention during a "terror attack" in Manipur's Jiribam district prevented the loss of several lives, Chief Minister N Biren Singh told NDTV on Thursday. Mr Singh said "10 Kuki terrorists" tried to enter a relief camp in Jiribam's Borobekra where 115 internally displaced people were living, but the CRPF foiled their plan. All the 10 were shot dead in a gunfight with the central forces on November 11 in Borobekra, a village on the interstate border with Assam. One CRPF soldier was injured. "If the CRPF was not deployed, the lives of many civilians would have been lost. The Kuki terrorists came with rocket launchers, AK 47, and many sophisticated weapons. They attacked the (police) camp , and killed two people on the spot," Mr Singh told NDTV. "They were trying to enter Borobekra relief camp where 115 Meitei civilians were living. But due to the timely intervention by the CRPF, the lives were saved. Otherwise that scenario could have been different. It's very unfortunate that eight innocent people were killed. The two died in the attack, and six including three small children were kidnapped and mercilessly killed. It is an intolerable crime," the Chief Minister said. Civil society groups and leaders of the Kuki tribes have claimed the 10 men were "village volunteers". The police have, however, called them "militants" and showed assault rifles and a rocket-propelled grenade (RPG) launcher as recovered from them. A bullet-ridden vehicle of the security forces was shown as one of the targets of the "militants". At least two dozen suspected Kuki militants had split into two groups before launching the attack in Borobekra, police sources had told NDTV. While one group took six Meitei hostages, the other group of 10 men vandalised and set fire to houses, and killed two senior citizens from the Meitei community. These 10 were later shot dead in the encounter with the CRPF, police sources have said. The six hostages were from the same family - a woman, her infant child, her two-year-old son, her mother, her sister and her sister's daughter - all were killed in captivity by suspected Kuki militants. Their bodies were dumped into a river . Days before the Borobekra attack, a mother of three from the Hmar tribe was allegedly raped and killed by suspected Meitei militants during a night attack on a village in Jiribam. Mr Singh said the Manipur cabinet's resolution was placed "after a lot of thought", adding the Centre sent more forces to catch the "militants". "You can't deal with Kuki militants without the forces. The operations have already started . This was the demand," he added. The Manipur cabinet has sought to declare the militants involved in the Jiribam terror attack of taking hostages and killing them as an unlawful organisation, or a terror group. He expressed confidence that the Centre would look into the controversial Armed Forces (Special Powers) Act, or AFSPA, by keeping in mind the "pulse of the people of Manipur" and will surely do something about it. The AFSPA, which gives sweeping powers to the security forces to operate in "disturbed areas" without fear of court proceedings, was reimposed in six police station areas of Manipur's valley region. Protests had also broken out in the valley areas when the partially decomposed bodies of the six hostages were found. The Chief Minister told NDTV that vandalism that happened during the protests was carried out by vested interests and rivals. "The people came out to protest in shock after hearing about the killings of the six innocent women and children. They were simply rallying and appealing to the government and MLAs, not involved in the violence. The arsonists stole many things from the houses they targeted. It was not the public. They were peacefully protesting, rallying. The troublemakers were the defeated group, politically desperate group, politically motivated gang, who looted and attacked homes. No one from the public attacked the MLAs' houses. The public was in the bazaar, protesting," Mr Singh said in the state capital Imphal. The Chief Minister said that in one MLA's house, some 600 people came and spoke to him, and after agreeing to their demands of bringing justice in the Jiribam terror attack case, the group of people left. "Another group of 200 or so people came. These were the ones who created trouble. We have identified them. There is video evidence. Most wore masks, but we know them. They have stolen gold, cash, even eight paddy bags from an MLA's house. What's all this?" Mr Singh said. On the much controversial War on Drugs campaign, the Chief Minister said at least 500 acres of poppy cultivation has been detected in Kangpokpi district, which sprang up fast as the security forces are tied up with other priority tasks. "Due to the present crisis, security has been tied up in some areas and cannot go out. Taking advantage of this, six villages in Kangpokpi are cultivating a huge amount of illegal poppy. Earlier, the forces used to go in the morning and evening to destroy illegal poppy cultivation. At least 500 acres are being cultivated," Mr Singh told NDTV. "We have asked the Chief Secretary to send forces to destroy the poppy farms in Kangpokpi before they can be harvested. They want to destroy the youth of Manipur by making them addicted to drugs, they want to harm India. They are using many strategies to invade India," he said. The Kuki tribes have often criticised Mr Singh for allegedly singling out the community and branding them as a people who encourage drug trafficking, even though many members of other communities have been arrested in narcotics cases. To bring peace in Manipur, Mr Singh said, the Centre had called both sides and started talks. "From the state government's side, we sent MLAs, leaders to Guwahati, Kolkata, Delhi for talks. Political dialogue, negotiations, interactions, these are the things that will help bring peace," he said. He faulted the media for allegedly not reporting the whole picture from Manipur, where he said trouble is confined to two-three districts, and not the entire state where people from different communities are living together in peace. "Differences between communities have been there for a long time. After my government came, I launched the go-to-hills campaign, go-to-village, meet with people from different communities, bring them together, we honoured every community, and constructed a museum of everyone's culture and traditions," the Chief Minister said. "The Sangai ethnic park has the model of houses of every tribe to show oneness... we are all proud Indians, we are all proud Manipuris, and almost succeeded except for the present scenario with this one community. But other communities are living together. Go to Imphal and see. There are churches, temples, masjids. Trouble is happening only in one-two districts, not the whole Manipur. The national media needs to be aware of all this," he said. When violence broke out in May 2023, temples were razed and set on fire in many hill areas, while churches in the valley areas also suffered the same fate. To a question about the National People's Party (NPP) withdrawing support to his government, Mr Singh told NDTV he is not worried. "The Congress has only five leaders. They won only five seats after 15 years... There's nothing to worry about. Whether the NPP withdraws or not, there is enough of a majority. Those who want to give an excuse at a time when the state is going through hardships, let them be. For example, if a lifeguard runs away when an incident is about to happen, let him run away. I am here to save everyone," he said. There are many villages of the Kuki tribes in the hills surrounding the Meitei-dominated valley. The clashes between the Meitei community and the nearly two dozen tribes known as Kukis - a term given by the British in colonial times - who are dominant in some hill areas of Manipur, has killed over 220 people and internally displaced nearly 50,000. The general category Meiteis want to be included under the Scheduled Tribes category, while the Kukis who share ethnic ties with people in neighbouring Myanmar's Chin State and Mizoram want a separate administration carved out of Manipur, citing discrimination and unequal share of resources and power with the Meiteis.
McDonald believes support for Sinn Féin higher than what polls show
TV’s Dr. Oz invested in businesses regulated by agency Trump wants him to leadFinding the perfect gift can be daunting. The only way to truly ensure you get it right would be to ask the recipient what they want, but that wouldn’t be much fun for either of you. Luckily, there’s another tactic to help you earn a “gift whisperer” reputation: seeking out unique, practical, game-changing gifts that will truly surprise and delight. But that’s about as easy as it sounds, which is to say it’s not easy at all. So, we’ve done the legwork for you. Start making your list with this compilation of some of the most innovative, functional and fun gifts of 2024. There’s something for every budget. This image provided by FinaMill shows the FinaMill Ultimate Spice Grinder Set. The new FinaMill Ultimate Spice Grinder set elevates the pedestrian pepper and spice mill in both function and style. Bear with me: The new FinaMill Ultimate Spice Grinder set elevates the pedestrian pepper and spice mill in both function and style. Available in three colors (Sangria Red, Midnight Black and Soft Cream), the rechargeable-battery unit grinds with a light touch rather than hand-tiring twists. That’s easier for everyone and especially helpful for those experiencing hand or wrist issues such as arthritis, carpal tunnel syndrome or tendinitis. And it’s fun to use. The set includes a stackable storage tray and four pods that can be easily swapped as needed: The GT microplane grater for hard spices, nuts and chocolate; the MAX for large spices and dried herbs; the ProPlus for smaller and oily spices; and the Pepper Pod for, well, pepper. $110. This image provided by Pull Start Fire shows the matchless fire igniter in use. Made of 89% recycled materials, the food-safe, eco-friendly, 3-by-2-by-1-inch fire starters will light a fire quickly without matches, lighters or kindling. Campers and backyard firepit lovers who have experienced the heartbreak of wet wood will appreciate having a three-pack of Pull Start Fire on hand. Made of 89% recycled materials, including sanding dust, wax and flint, the food-safe, eco-friendly, 3-by-2-by-1-inch fire starters will light a fire quickly without matches, lighters or kindling. Just loop the attached green string around a log, incorporate it into a wood stack, and pull the attached red string to ignite. Each windproof, rainproof block burns for 30 minutes. $29.99. This image provided by Souper Cubes shows No Mess Utensils held upright on pot edges. The No Mess Utensil lives up to its name. The utensils, a serving spoon and a ladle, have innovative, S-shaped handles designed to rest on the edge of a pot. The No Mess Utensil Set from Souper Cubes , a company known for its portioned, silicone freezer trays, lives up to its name. The utensils — a serving spoon and a ladle — have innovative, S-shaped handles designed to rest on the edge of a pot, keeping them upright so they won’t slip in. The design also eliminates the need for a spoon rest or, worse, placing dirty utensils on the kitchen counter or stovetop between stirs. A silicone coating in a choice of Aqua, Charcoal, Cranberry or Blueberry keeps handles cool to the touch. $24.99. This image provided by FeatherSnap shows a female cardinal bird perched on a FeatherSnap Wi-Fi Solar Powered Camera Smart Bird Feeder. Equipped with an HD camera, the dual-chamber feeder enables up-close livestreaming of avian visitors, as well as species-logging via the free mobile app. The FeatherSnap Wi-Fi smart bird feeder could turn anyone into an avid birdwatcher. Equipped with an HD camera, the dual-chamber feeder enables up-close livestreaming of avian visitors, as well as species-logging via the free mobile app. An optional premium subscription ($59.99 annually or $6.99 monthly) includes unlimited photo and video storage, AI identification with species-specific details, and the opportunity to earn badges for logging new visitors. Turn on notifications to get alerts sent to your phone whenever there’s activity at the feeder. $179.99. This image provided by FUJIFILM North America Corporation and FUJIFILM Corporation Tokyo shows a smartphone printer. Fujifilm Instax's Mini Link 3 smartphone printer offers a touch of nostalgia without sacrificing technology. Just load the printer with film and connect it to your Android or iOS device via Bluetooth to print wallet-size photos. Fujifilm's Instax Mini Link 3 smartphone printer offers a touch of nostalgia without sacrificing technology. Just load the 4.9-by-3.5-by-1.3-inch printer with Instax Mini instant film and connect it to your Android or iOS device via Bluetooth to print wallet-size photos. If you want to get fancy, you can adjust brightness, contrast and saturation, or apply filters, including 3D augmented-reality effects, via the free Instax Mini Link app. It can also make collages of up to six images, or animate photos to share on social media. Available in Rose Pink, Clay White and Sage Green. $99.95. This image provided by easyplant shows a Marxii Calathea plant in a small, beige, self-watering pot. The appropriately named easyplant is one of the best gifts you can give your houseplant-loving friends, regardless of their experience level. The appropriately named easyplant is one of the best gifts you can give your houseplant-loving friends, regardless of their experience level. Select a pot color, size and plant (or get recommendations based on sunlight requirements, pet friendliness and other attributes) and fill the self-watering container’s built-in reservoir roughly once a month. Moisture will permeate the soil from the bottom as needed, eliminating the often-fatal consequences of over- or under-watering. It’s also a literal lifesaver come vacation time. $49-$259. This image provided by Nama shows the M1 plant-based milk maker. If you've got a no-dairy friend on your list, a plant-based milk maker could save them money while allowing them to avoid unnecessary ingredients like sugar, stabilizers, thickeners and preservatives. If you’ve got a no-dairy friend on your list, a plant-based milk maker could save them money while allowing them to avoid sugar, stabilizers, thickeners and preservatives. The Nama M1 appliance both blends and strains ingredients, converting nuts, seeds, grains or oats into velvety-smooth milk in just one minute, with zero grit. And for zero waste, the pasty leftover pulp can be used in other recipes for added nutrients. The device also makes infused oils, flavored waters and soups. And, importantly, cleanup is easy. Available in white and black. $400. This image provided by QelviQ shows a wine bottle chiller. For friends who prefer stronger beverages, the QelviQ personal sommelier uses "smart" technology to ensure wine is served at its ideal temperature. For friends who prefer stronger beverages, the QelviQ personal sommelier uses “smart” technology to ensure wine is served at its ideal temperature. Unlike traditional wine refrigerators, this device doesn’t take up any floor space. It also doesn’t chill wine to just one or two temperatures based on its color. Instead — paired with the free QelviQ app — the tabletop chiller relies on a database of more than 350,000 wines to bring a bottle to its specific recommended serving temperature in as little as 20 minutes. It also suggests food-wine and wine-food pairings. Plus, the appliance serves as a great icebreaker to inspire dinnertime conversation. Available in Exciting Red, Dashing Black and Dreamy White. $495. This image provided by Uncommon Goods shows a 2-piece LED Grilling Tool Set. Uncommon Good's 2-piece LED Grilling Tool Set puts illumination into the handles of its stainless-steel spatula and tongs. Grilling food after dark — and ascertaining its doneness — can prove challenging without outdoor lighting, and it’s nearly impossible to cook while holding a flashlight. But as is often the case, the simplest of solutions can make the biggest of impacts: Uncommon Good’s 2-piece LED Grilling Tool Set puts illumination into the handles of its stainless-steel spatula and tongs. After use, the lights can be removed and the utensils run through the dishwasher. $40. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. With our weekly newsletter packed with the latest in everything food.
Panthers TE Ja'Tavion Sanders carted off field for neck injury
Michigan's defense of national title fell short, aims to cap lost season with win against Ohio StateDarius Tahir | (TNS) KFF Health News President-elect Donald Trump’s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace — celebrity doctor Mehmet Oz — recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest. Oz’s holdings, some shared with family, included a stake in UnitedHealth Group worth as much as $600,000, as well as shares of pharmaceutical firms and tech companies with business in the health care sector, such as Amazon. Collectively, Oz’s investments total tens of millions of dollars, according to financial disclosures he filed during his failed 2022 run for a Pennsylvania U.S. Senate seat. Trump said Tuesday he would nominate Oz as administrator of the Centers for Medicare & Medicaid Services. The agency’s scope is huge: CMS oversees coverage for more than 160 million Americans, nearly half the population. Medicare alone accounts for approximately $1 trillion in annual spending, with over 67 million enrollees. UnitedHealth Group is one of the largest health care companies in the nation and arguably the most important business partner of CMS, through which it is the leading provider of commercial health plans available to Medicare beneficiaries. UnitedHealth also offers managed-care plans under Medicaid, the joint state-federal program for low-income people, and sells plans on government-run marketplaces set up via the Affordable Care Act. Oz also had smaller stakes in CVS Health, which now includes the insurer Aetna, and in the insurer Cigna. It’s not clear if Oz, a heart surgeon by training, still holds investments in health care companies, or if he would divest his shares or otherwise seek to mitigate conflicts of interest should he be confirmed by the Senate. Reached by phone on Wednesday, he said he was in a Zoom meeting and declined to comment. An assistant did not reply to an email message with detailed questions. “It’s obvious that over the years he’s cultivated an interest in the pharmaceutical industry and the insurance industry,” said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group. “That raises a question of whether he can be trusted to act on behalf of the American people.” (The publisher of KFF Health News, David Rousseau, is on the CSPI board .) Oz used his TikTok page on multiple occasions in November to praise Trump and Robert F. Kennedy Jr., including their efforts to take on the “illness-industrial complex,” and he slammed “so-called experts like the big medical societies” for dishing out what he called bad nutritional advice. Oz’s positions on health policy have been chameleonic; in 2010, he cut an ad urging Californians to sign up for insurance under President Barack Obama’s Affordable Care Act, telling viewers they had a “historic opportunity.” Oz’s 2022 financial disclosures show that the television star invested a substantial part of his wealth in health care and food firms. Were he confirmed to run CMS, his job would involve interacting with giants of the industry that have contributed to his wealth. Given the breadth of his investments, it would be difficult for Oz to recuse himself from matters affecting his assets, if he still holds them. “He could spend his time in a rocking chair” if that happened, Lurie said. In the past, nominees for government positions with similar potential conflicts of interest have chosen to sell the assets or otherwise divest themselves. For instance, Treasury Secretary Janet Yellen and Attorney General Merrick Garland agreed to divest their holdings in relevant, publicly traded companies when they joined the Biden administration. Trump, however, declined in his first term to relinquish control of his own companies and other assets while in office, and he isn’t expected to do so in his second term. He has not publicly indicated concern about his subordinates’ financial holdings. CMS’ main job is to administer Medicare. About half of new enrollees now choose Medicare Advantage, in which commercial insurers provide their health coverage, instead of the traditional, government-run program, according to an analysis from KFF, a health information nonprofit that includes KFF Health News. Proponents of Medicare Advantage say the private plans offer more compelling services than the government and better manage the costs of care. Critics note that Medicare Advantage plans have a long history of costing taxpayers more than the traditional program. UnitedHealth, CVS, and Cigna are all substantial players in the Medicare Advantage market. It’s not always a good relationship with the government. The Department of Justice filed a 2017 complaint against UnitedHealth alleging the company used false information to inflate charges to the government. The case is ongoing. Oz is an enthusiastic proponent of Medicare Advantage. In 2020, he proposed offering Medicare Advantage to all; during his Senate run, he offered a more general pledge to expand those plans. After Trump announced Oz’s nomination for CMS, Jeffrey Singer, a senior fellow at the libertarian-leaning Cato Institute, said he was “uncertain about Dr. Oz’s familiarity with health care financing and economics.” Singer said Oz’s Medicare Advantage proposal could require large new taxes — perhaps a 20% payroll tax — to implement. Oz has gotten a mixed reception from elsewhere in Washington. Pennsylvania Sen. John Fetterman, the Democrat who defeated Oz in 2022, signaled he’d potentially support his appointment to CMS. “If Dr. Oz is about protecting and preserving Medicare and Medicaid, I’m voting for the dude,” he said on the social platform X. Oz’s investments in companies doing business with the federal government don’t end with big insurers. He and his family also hold hospital stocks, according to his 2022 disclosure, as well as a stake in Amazon worth as much as nearly $2.4 million. (Candidates for federal office are required to disclose a broad range of values for their holdings, not a specific figure.) Amazon operates an internet pharmacy, and the company announced in June that its subscription service is available to Medicare enrollees. It also owns a primary care service , One Medical, that accepts Medicare and “select” Medicare Advantage plans. Oz was also directly invested in several large pharmaceutical companies and, through investments in venture capital funds, indirectly invested in other biotech and vaccine firms. Big Pharma has been a frequent target of criticism and sometimes conspiracy theories from Trump and his allies. Kennedy, whom Trump has said he’ll nominate to be Health and Human Services secretary, is a longtime anti-vaccine activist. During the Biden administration, Congress gave Medicare authority to negotiate with drug companies over their prices. CMS initially selected 10 drugs. Those drugs collectively accounted for $50.5 billion in spending between June 1, 2022, and May 31, 2023, under Medicare’s Part D prescription drug benefit. At least four of those 10 medications are manufactured by companies in which Oz held stock, worth as much as about $50,000. Related Articles National Politics | Special counsel moves to dismiss election interference case against President-elect Donald Trump National Politics | Donald Trump Jr. emerges as a political force of his own as he helps his father launch a second term National Politics | The rising price of paying the national debt is a risk for Trump’s promises on growth and inflation National Politics | What to know about Brooke Rollins, Trump’s pick for agriculture secretary National Politics | After Trump’s Project 2025 denials, he is tapping its authors and influencers for key roles Oz may gain or lose financially from other Trump administration proposals. For example, as of 2022, Oz held investments worth as much as $6 million in fertility treatment providers. To counter fears that politicians who oppose abortion would ban in vitro fertilization, Trump floated during his campaign making in vitro fertilization treatment free. It’s unclear whether the government would pay for the services. In his TikTok videos from earlier in November, Oz echoed attacks on the food industry by Kennedy and other figures in his “Make America Healthy Again” movement. They blame processed foods and underregulation of the industry for the poor health of many Americans, concerns shared by many Democrats and more mainstream experts. But in 2022, Oz owned stakes worth as much as $80,000 in Domino’s Pizza, Pepsi, and US Foods, as well as more substantial investments in other parts of the food chain, including cattle; Oz reported investments worth as much as $5.5 million in a farm and livestock, as well as a stake in a dairy-free milk startup. He was also indirectly invested in the restaurant chain Epic Burger. One of his largest investments was in the Pennsylvania-based convenience store chain Wawa, which sells fast food and all manner of ultra-processed snacks. Oz and his wife reported a stake in the company, beloved by many Pennsylvanians, worth as much as $30 million. ©2024 KFF Health News. Distributed by Tribune Content Agency, LLC.
Chuck Woolery, smooth-talking game show host of 'Love Connection' and 'Scrabble,' dies at 83Global Hydrographic Survey Equipment Market Set For 9.5% Growth, Reaching $4.15 Billion By 2028HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /CNW/ -- Innocan Pharma Corporation INNO IP INNPF (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio. During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT - CBD ( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LPT-CBD as a treatment for chronic pain in humans. Additionally, the FDA acknowledged LPT-CBD's development under the 505(b)(2) regulatory pathway, which provides Innocan with an accelerated route to patent utilization and commercialization. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. Iris Bincovich, CEO of Innocan Pharma, commented: "In 2024, we not only met but surpassed our FDA-related goals, achieving regulatory milestones ahead of schedule. With the FDA 505(b)(2) regulatory pathway meeting behind us, these advancements position us to accelerate our development in 2025, bringing us closer to delivering innovative pain management solutions for both human and veterinary applications." The 505(b)(2) FDA regulatory pathway offers a streamlined approach for developing a long-acting injectable cannabinoid using a liposomal drug delivery platform to treat chronic pain. By leveraging existing pre-clinical data from approved products, this pathway is expected to significantly shorten both development time and cost. This pathway facilitates innovative formulations like liposomal delivery, by allowing for modifications to dosage forms, administration routes, or drug combinations, all while adhering to stringent safety and efficacy standards. This approach is expected to accelerate market entry and address unmet medical needs in chronic pain management. Company ' s Update on its Activity in Research and Development and FDA interactions On February 26, 2024 , the Company announced the latest findings from the Company's pharmacokinetic study of its liposome CBD platform ("LPT-CBD") in rabbits. In agreement with studies conducted in other animals (mice, dogs, goats, and sheep) this study resulted in prolonged exposure of CBD obtained following a single subcutaneous LPT-CBD injection. This data along with data obtained from other organisms injected with the Company's liposomal CBD, consistently demonstrates that a detectable CBD level could be maintained for weeks following a single injection. On March 5, 2024 , the Company announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. In this study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (BBB) and deliver long brain exposure. On April 22, 2024 , the Company announced that it had submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for LPT-CBD. Innocan's Pre-IND meeting request letter to the FDA represents a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. The objective of the Pre-IND meeting is to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an investigational new drug ("IND") program in the United States . On May 9, 2024 , the Company announced the successful pre-clinical treatment of amputee female donkey with a liposomal-CBD injection. Miri, a-7-year-old female donkey, had undergone amputation of her right front limb, leaving the weight burden primarily on her left front limb. This led to an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. In a compassionate act, Miri was administered a liposomal-CBD injection. The effect was immediate as Miri regained her ability to walk and move as she had before her inflammatory disease developed. On May 21, 2024 , the Company announced significant advancements in the regulatory process for its LPT - CBD, which provides an innovative solution in non-opioid pain management. The FDA granted Innocan an INAD number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA was on July 31, 2024 , where Innocan presented its preclinical results and proposed clinical development plan. The meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. On June 11, 2024 , the Company announced the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. Recognized by the FDA as an excellent model for toxicology, minipigs are small breeds of miniature domestic pigs which share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. The animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions. On July 2, 2024 , the Company announced that it engaged the Past President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to Innocan's team during the LPT-CBD submission process with the FDA. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. On July 26, 2024 , the Company announced that the CVM) granted the Company a sponsor fee waiver and assigned an INAD number for its LPT-CBD product. This represented a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the Company a sponsor fee waiver for fiscal year 2024. Over the past year, repeated administration of LPT-CBD in dogs and other animals demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. On September 3, 2024 , the Company announced that it received a positive response from the FDA following Innocan's successful pre-IND Type B meeting with the FDA held in July, for its lead drug product LPT-CBD. The FDA has agreed to LPT-CBD's submission under the 505(b)(2) New Drug Application (NDA) by establishing a scientific bridge to the reference listed drug. The 505(b)(2) abbreviated pathway, as it is often described, typically enables a faster route to patent utilization and commercial approval. This pathway is a significant milestone for Innocan, as it may pave the way for a streamlined and accelerated FDA approval process for LPT-CBD, while allowing Innocan to advance its patent protected innovation. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed IND filing for a Phase I clinical study. On October 9, 2024 , The Company announced that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of the Company's Scientific Advisory Board, was recognized among the top 2% most cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices. Dr. Pergolizzi was appointed to be part of Innocan's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications. His expertise in pain management, critical care medicine, and regulatory processes are key in advancing the issuer's pharmaceutical developments. On October 11, 2024 , the Company announced promising results from a multi-year compassionate therapy using repeated LPT-CBD injections for pain relief in dogs with naturally occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased well-being which was clearly noticeable. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively after their owners reported significant improvement in quality of life, receiving the treatment in addition to other conventional treatments. About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO +1-516-210-4025 +972-54-3012842 +44 203 769 9377 info@innocanpharma.com NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry and potential for patent utilization and commercialization is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg View original content: https://www.prnewswire.com/news-releases/innocan-pharma-provides-its-annual-state-of-research-and-development-update-for-2024-302330659.html SOURCE Innocan Pharma Corporation View original content: http://www.newswire.ca/en/releases/archive/December2024/12/c7609.html © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Chuck Woolery, smooth-talking game show host of 'Love Connection' and 'Scrabble,' dies at 83